TGFB1 and Hepatic fibrosis: A study showed that methyl helicterate could mitigate liver fibrosis by inhibiting miR-21-mediated ERK and TGFβ/SMAD 2/3 pathways and, therefore, has potential as a therapeutic drug for liver fibrosis (Huang et al., 2019).